Emily Eller and Kevin Frymire on pharma’s automation dangers

Share on facebook
Share on twitter
Share on linkedin

For pharmaceutical companies, automation of data processes can increase efficiencies, enable close-to-real-time reporting and equip executives to make faster decisions. But just as automation has contributed to disasters in the airline industry, it can pose significant challenges for pharmaceutical commercial teams. Emily Eller and Kevin Frymire explain how to avoid the dangers of automation in Pharmaceutical Executive.